, /PRNewswire/ -- The global osteoarthritis therapeutics market size is estimated to grow by .57 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 9.
49% during the forecast period. Increasing incidence of osteoarthritis is driving market growth, with a trend towards expanding research and development. However, high cost of treatment poses a challenge.
Key market players include Abbott Laboratories, Alvogen Iceland ehf, Anika Therapeutics Inc., Avanos Medical Inc., Bayer AG, Bioventus LLC, Boehringer Ingelheim International GmbH, F.
Hoffmann La Roche Ltd., Ferring BV, Fidia Farmaceutici Spa, GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd.
, Horizon Therapeutics Plc, Johnson and Johnson Services Inc., Novartis AG, Pacira BioSciences Inc., Pharmed Ltd.
, Sanofi SA, Viatris Inc., and Zimmer Biomet Holdings Inc..
Get a detailed analysis on regions, market segments, customer landscape, and companies- The Osteoarthritis (OA) Therapeutics Market is experiencing growth due to advancements in research and development, leading to the identification of drug targets for disease-modifying drugs. IL-1beta and TNF-alpha, key proinflammatory cytokines contributing to cartilage breakdown, are under evaluation. Growth factors like IGF-1, BFGF, PDGF, BMPs, and TGF-beta 1, involved in cartilage repair, are also being explored.
G-protein-coupled receptors for bradykinin, chemokines, and calcitonin gene-related peptides, as well as voltage-sensitive calcium.
